IL-17 and -23 Inhibitors for the Treatment of Psoriasis
Psoriasis is a chronic inflammatory skin condition with a significant global burden of disease and a wide array of potential treatment options, ranging from topical to systemic therapies. There are currently 11 biologic agents approved by the U.S. Food and Drug Administration (FDA) for the treatmen...
Main Authors: | Sonali Batta, Ramlah Khan, Marcus Zaayman, Allison Limmer, Dario Kivelevitch, Alan Menter |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2023-04-01
|
Series: | European Medical Journal Allergy & Immunology |
Online Access: | https://www.emjreviews.com/allergy-immunology/article/il-17-and-23-inhibitors-for-the-treatment-of-psoriasis/ |
Similar Items
-
How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis
by: Mina Amin, et al.
Published: (2019-05-01) -
Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
by: Yu-Huei Huang, et al.
Published: (2023-02-01) -
Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
by: Caleb Jeon, et al.
Published: (2017-10-01) -
Review of IL-17 inhibitors for psoriasis
by: Mina Amin, et al.
Published: (2018-05-01) -
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
by: Paolo Dapavo, et al.
Published: (2022-05-01)